825 results on '"Ghanima, Waleed"'
Search Results
102. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial
103. Prevention of post-thrombotic syndrome with rosuvastatin: A multicenter randomized controlled pilot trial (SAVER)
104. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia
105. Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (ERCI) network
106. Thromboembolic complications during and after hospitalization for COVID-19: Incidence, risk factors and thromboprophylaxis
107. Additional file 2 of How do patients and physicians perceive immune thrombocytopenia (ITP) as a disease? Results from Indian analysis of ITP World Impact Survey (I-WISh)
108. High circulating levels of the homeostatic chemokines CCL19 and CCL21 predict mortality and disease severity in Covid-19
109. Statins for venous event reduction in patients with venous thromboembolism: A multicenter randomized controlled pilot trial assessing feasibility
110. Association between myocardial fibrosis, as assessed with cardiac magnetic resonance T1 mapping, and persistent dyspnea after pulmonary embolism
111. Safety and Efficiency of Diagnostic Strategies for Ruling Out Pulmonary Embolism in Clinically Relevant Patient Subgroups
112. External Validation of the Patient-Reported Villalta Scale for the Diagnosis of Postthrombotic Syndrome
113. Faktor Xa-hemmere til forebygging og behandling av venøs tromboembolisme ved kreft.
114. An observational study to identify the prevalence of thrombocytopenia and anti‐PF4/polyanion antibodies in Norwegian health care workers after COVID‐19 vaccination
115. Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study)
116. Pharmacokinetic / Pharmacodynamic (PK/PD) Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia
117. LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia
118. Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia
119. Low Dose Apixaban As Secondary Prophylaxis for Venous Thromboembolism in Cancer Patients, 30 Months Follow-up
120. Efficacy and safety of a 12-week outpatient pulmonary rehabilitation program in Post-PE Syndrome
121. Quality of life after COVID-19 without hospitalisation: Good overall, but reduced in some dimensions
122. Lessons learned using real‐world data to emulate randomized trials—a case study of treatment effectiveness for newly diagnosed immune thrombocytopenia
123. How Do Patients and Physicians Perceive Immune Thrombocytopenia (ITP) As a Disease? Results From Indian Analysis of ITP World Impact Survey (I-WISh)
124. Qualitative study to support the content validity of the immune thrombocytopenia (ITP) Life Quality Index (ILQI)
125. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study
126. Additional file 2 of Pulmonary rehabilitation to improve physical capacity, dyspnea, and quality of life following pulmonary embolism (the PeRehab study): study protocol for a two-center randomized controlled trial
127. Additional file 1 of Pulmonary rehabilitation to improve physical capacity, dyspnea, and quality of life following pulmonary embolism (the PeRehab study): study protocol for a two-center randomized controlled trial
128. Immune thrombocytopenia (ITP) World Impact Survey (I-WISh):Impact of ITP on health-related quality of life
129. Efficacy and safety of a 12-week outpatient pulmonary rehabilitation program in Post-PE Syndrome
130. Cost-effectiveness of magnetic resonance imaging for diagnosing recurrent ipsilateral deep vein thrombosis
131. A Phase III Clinical Trial Program Investigating the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (VAYHIT1 and VAYHIT2) and Warm Autoimmune Hemolytic Anemia (VAYHIA)
132. Interim Baseline Characteristics of Adult Patients with Immune Thrombocytopenia Enrolled in the Observational Multicenter Phase 4 Adopt Study to Evaluate the Use and Effectiveness of Avatrombopag
133. The Lack of Tolerable Treatments Options That Can Induce Durable Responses without Fear of Relapse after Discontinuation Represents a Significant Unmet Need for Patients (Pts) with Immune Thrombocytopenia (ITP): Results from the ITP World Impact Survey (I-WISh) 2.0
134. Impact of Age on Hemostasis of Patients with Immune Thrombocytopenia
135. Coagulation in Patients with Immune Thrombocytopenia and Other Associated Autoimmune Disorders
136. Health Related Quality of Life in Patients with Primary ITP Compared with Population Norms: A Multicenter Retrospective Analysis of Data from Norwegian ITP Registry
137. Ianalumab, a Novel Anti-B-Cell Activating Factor (BAFF) Receptor (BAFF-R) Monoclonal Antibody (mAb) in Development for Immune Thrombocytopenia (ITP) and Warm Autoimmune Hemolytic Anemia (wAIHA), Has Demonstrated a Favorable Safety Profile in Sjögren's Syndrome (SjS), Systemic Lupus Erythematosus (SLE) and Chronic Lymphocytic Leukemia (CLL)
138. Real-World Use, Effectiveness and Safety of Romiplostim, Eltrombopag and Avatrombopag in Immune Thrombocytopenia: Data from the Norwegian ITP Registry
139. Avatrombopag Plus Fostamatinib Combination Efficacy and Safety in Patients with Immune Thrombocytopenia
140. Validation of Differentially Expressed Micrornas in Primary Immune Thrombocytopenia Suggests Mir-199a-5p Is a Potential Diagnostic Biomarker
141. Patient Experience with Signs, Symptoms, and Daily Impacts of Immune Thrombocytopenia
142. Pain and bleeding associated with trephine biopsy
143. Fatigue after initiating rivaroxaban for venous thromboembolism
144. Incidence of thrombotic complications in hospitalised and non‐hospitalised patients after COVID‐19 diagnosis
145. How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment
146. Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation
147. Pulmonary and cardiac variables associated with persistent dyspnea after pulmonary embolism
148. External Validation of the Patient-Reported Villalta Scale for the Diagnosis of Postthrombotic Syndrome.
149. Predictors for and outcomes after bone marrow biopsy in Scandinavian patients with chronic immune thrombocytopenia
150. sj-pdf-2-acr-10.1177_0284185120966724 - Supplemental material for The mean bilateral proximal extension of the clot is associated with pulmonary embolism severity parameters and management-associated outcomes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.